Research peptide · GHRH(1-29)-amide
Sermorelin Acetate 5 mg
Sermorelin Acetate 5 mg GHRH fragment research material. Select 1, 2 or 3 vials for 5, 10 or 15 mg total content.
Research peptide · GHRH(1-29)-amide
Sermorelin Acetate 5 mg GHRH fragment research material. Select 1, 2 or 3 vials for 5, 10 or 15 mg total content.
Research peptide · GHRH(1-29)-amide
Sermorelin Acetate 5 mg GHRH fragment research material. Select 1, 2 or 3 vials for 5, 10 or 15 mg total content.
No reviews yet. Be the first to share your experience.
No reviews yet. Be the first to share your experience.
/ vial
Order today → Delivery Thu, Nov 12 – Fri, Nov 20 to United States
/ vial
Order today → Delivery Thu, Nov 12 – Fri, Nov 20 to United States
Independently verified quality
3,000+
satisfied researchers
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
3,000+ satisfied researchers
Sermorelin Acetate 5 mg - 1 Vial vial + 2 ml BAC water → concentration:
Per unit (10 IU)
0.25 mg
Research details
Sermorelin is the biologically active GHRH(1-29)-amide fragment, comprising 29 amino acids. Sermorelin Acetate is an established name for this form and places the material within research on growth hormone-releasing hormone signaling.
Each vial contains 5 mg of Sermorelin Acetate. This material is supplied for research use only and is not a medicine or a product intended for human or animal use.
Sermorelin represents the first 29 amino acids of growth hormone-releasing hormone in an amidated fragment. It is studied in relation to the GHRH receptor and the signalling involved in growth hormone release. Its molecular identity differs from longer GHRH analogues and modified compounds with different pharmacokinetic properties.
Analytical research has examined the identification of GHRH-related peptides and their metabolites in plasma. This provides a scientific context for distinguishing intact material from degradation products. The acetate form identifies the salt form supplied here; it does not define an administration protocol.
Select one vial for 5 mg total content, two vials for 10 mg, or three vials for 15 mg. Each vial retains the stated 5 mg strength.
The selected pack changes the number of individually supplied vials. It does not change the 5 mg content of an individual vial.
Qualitative identification of growth hormone-releasing hormones in human plasma
GHRH receptor agonist: amidated GHRH(1-29) fragment.
Advanced protocol
250-500 mcg before bed, subcutaneously
Note: The dosages listed correspond to typical ranges from published research literature. They do not replace advice from a qualified researcher or physician.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.43% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
It is the 29-amino-acid GHRH(1-29)-amide fragment in acetate form.
Independently verified quality
3,000+
satisfied researchers
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
99.43%
Avg. purity 2026
4.8 ★
ProvenExpert
3,000+ satisfied researchers
Sermorelin Acetate 5 mg - 1 Vial vial + 2 ml BAC water → concentration:
Per unit (10 IU)
0.25 mg
Research details
Sermorelin is the biologically active GHRH(1-29)-amide fragment, comprising 29 amino acids. Sermorelin Acetate is an established name for this form and places the material within research on growth hormone-releasing hormone signaling.
Each vial contains 5 mg of Sermorelin Acetate. This material is supplied for research use only and is not a medicine or a product intended for human or animal use.
Sermorelin represents the first 29 amino acids of growth hormone-releasing hormone in an amidated fragment. It is studied in relation to the GHRH receptor and the signalling involved in growth hormone release. Its molecular identity differs from longer GHRH analogues and modified compounds with different pharmacokinetic properties.
Analytical research has examined the identification of GHRH-related peptides and their metabolites in plasma. This provides a scientific context for distinguishing intact material from degradation products. The acetate form identifies the salt form supplied here; it does not define an administration protocol.
Select one vial for 5 mg total content, two vials for 10 mg, or three vials for 15 mg. Each vial retains the stated 5 mg strength.
The selected pack changes the number of individually supplied vials. It does not change the 5 mg content of an individual vial.
Qualitative identification of growth hormone-releasing hormones in human plasma
GHRH receptor agonist: amidated GHRH(1-29) fragment.
Advanced protocol
250-500 mcg before bed, subcutaneously
Note: The dosages listed correspond to typical ranges from published research literature. They do not replace advice from a qualified researcher or physician.
Every batch is analyzed by an independent laboratory via HPLC before shipment. We document purity (avg. 99.43% in 2026), mass spectrometry identity, and sterility. Production follows GMP standards in ISO-certified laboratories.
It is the 29-amino-acid GHRH(1-29)-amide fragment in acetate form.
